Johnson & Johnson

Insider sales reveal routine portfolio moves, not a confidence loss—J&J’s Kenvue spin‑off, tech‑driven specialty strategy, and robust cost cuts keep growth on track.

Johnson & Johnson CEO Duato Joaquin sells 100k shares—exploring the motives, market sentiment, and what this means for investors and the company’s future.